ZA200501176B - Platinum aggregates and process for producing the same - Google Patents

Platinum aggregates and process for producing the same Download PDF

Info

Publication number: ZA200501176B
Authority: ZA; South Africa
Prior art keywords: lipid; platinum compound; temperature; cisplatin; composition
Prior art date: 2002-08-02

Application number

ZA200501176A

Other languages

English (en)

Inventor

Jin Lee

Brian S Miller

Fangjun Wu

Lawrence T Boni

Original Assignee

Transave Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-08-02

Filing date

2005-02-09

Publication date

2006-09-27

2005-02-09 Application filed by Transave Inc filed Critical Transave Inc

2006-09-27 Publication of ZA200501176B publication Critical patent/ZA200501176B/en

Links

238000000034 method Methods 0.000 title claims description 62
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 title claims description 30
229910052697 platinum Inorganic materials 0.000 title claims description 15
150000002632 lipids Chemical class 0.000 claims description 102
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 84
229960004316 cisplatin Drugs 0.000 claims description 83
239000000203 mixture Substances 0.000 claims description 46
239000002502 liposome Substances 0.000 claims description 39
150000003058 platinum compounds Chemical class 0.000 claims description 38
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 34
239000000243 solution Substances 0.000 claims description 24
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 21
235000012000 cholesterol Nutrition 0.000 claims description 17
230000002209 hydrophobic effect Effects 0.000 claims description 10
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 9
239000011159 matrix material Substances 0.000 claims description 9
239000012736 aqueous medium Substances 0.000 claims description 6
239000012528 membrane Substances 0.000 claims description 6
238000002347 injection Methods 0.000 claims description 5
239000007924 injection Substances 0.000 claims description 5
239000008194 pharmaceutical composition Substances 0.000 claims description 4
238000005538 encapsulation Methods 0.000 claims description 3
238000001914 filtration Methods 0.000 claims description 3
239000003085 diluting agent Substances 0.000 claims description 2
239000003937 drug carrier Substances 0.000 claims description 2
239000007788 liquid Substances 0.000 claims description 2
KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims 4
238000001816 cooling Methods 0.000 description 25
238000010792 warming Methods 0.000 description 24
239000012867 bioactive agent Substances 0.000 description 16
239000000523 sample Substances 0.000 description 16
239000002904 solvent Substances 0.000 description 11
229940079593 drug Drugs 0.000 description 10
239000003814 drug Substances 0.000 description 10
238000001802 infusion Methods 0.000 description 10
238000009472 formulation Methods 0.000 description 9
PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
206010028980 Neoplasm Diseases 0.000 description 8
238000000502 dialysis Methods 0.000 description 7
230000036571 hydration Effects 0.000 description 7
238000006703 hydration reaction Methods 0.000 description 7
150000003904 phospholipids Chemical class 0.000 description 7
230000001351 cycling effect Effects 0.000 description 6
238000004519 manufacturing process Methods 0.000 description 6
229940045985 antineoplastic platinum compound Drugs 0.000 description 5
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 5
239000000725 suspension Substances 0.000 description 5
201000011510 cancer Diseases 0.000 description 4
SOCTUWSJJQCPFX-UHFFFAOYSA-N dichromate(2-) Chemical compound [O-][Cr](=O)(=O)O[Cr]([O-])(=O)=O SOCTUWSJJQCPFX-UHFFFAOYSA-N 0.000 description 4
235000014113 dietary fatty acids Nutrition 0.000 description 4
239000006185 dispersion Substances 0.000 description 4
229930195729 fatty acid Natural products 0.000 description 4
239000000194 fatty acid Substances 0.000 description 4
150000004665 fatty acids Chemical class 0.000 description 4
235000010469 Glycine max Nutrition 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
239000013543 active substance Substances 0.000 description 3
239000002246 antineoplastic agent Substances 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
239000002872 contrast media Substances 0.000 description 3
230000000694 effects Effects 0.000 description 3
239000010408 film Substances 0.000 description 3
238000007710 freezing Methods 0.000 description 3
230000008014 freezing Effects 0.000 description 3
NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 description 2
BIABMEZBCHDPBV-MPQUPPDSSA-N 1,2-palmitoyl-sn-glycero-3-phospho-(1'-sn-glycerol) Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCCCC BIABMEZBCHDPBV-MPQUPPDSSA-N 0.000 description 2
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
244000068988 Glycine max Species 0.000 description 2
239000000232 Lipid Bilayer Substances 0.000 description 2
FVJZSBGHRPJMMA-IOLBBIBUSA-N PG(18:0/18:0) Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCCCCCC FVJZSBGHRPJMMA-IOLBBIBUSA-N 0.000 description 2
241000700605 Viruses Species 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
229960001231 choline Drugs 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
230000008021 deposition Effects 0.000 description 2
229960005160 dimyristoylphosphatidylglycerol Drugs 0.000 description 2
BPHQZTVXXXJVHI-AJQTZOPKSA-N ditetradecanoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCC BPHQZTVXXXJVHI-AJQTZOPKSA-N 0.000 description 2
239000012467 final product Substances 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
238000005259 measurement Methods 0.000 description 2
238000002156 mixing Methods 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
239000003791 organic solvent mixture Substances 0.000 description 2
239000012466 permeate Substances 0.000 description 2
150000008104 phosphatidylethanolamines Chemical class 0.000 description 2
239000000047 product Substances 0.000 description 2
238000010791 quenching Methods 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
238000003860 storage Methods 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 description 1
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
BOBLSBAZCVBABY-WPWUJOAOSA-N 1,6-diphenylhexatriene Chemical compound C=1C=CC=CC=1\C=C\C=C\C=C\C1=CC=CC=C1 BOBLSBAZCVBABY-WPWUJOAOSA-N 0.000 description 1
PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
ZKARERKEBVSZCX-VMDDUYISSA-M 4-methylbenzenesulfonate;trimethyl-[4-[(1e,3e,5e)-6-phenylhexa-1,3,5-trienyl]phenyl]azanium Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1.C1=CC([N+](C)(C)C)=CC=C1\C=C\C=C\C=C\C1=CC=CC=C1 ZKARERKEBVSZCX-VMDDUYISSA-M 0.000 description 1
206010005056 Bladder neoplasm Diseases 0.000 description 1
102000004506 Blood Proteins Human genes 0.000 description 1
108010017384 Blood Proteins Proteins 0.000 description 1
FZLOAWVDEJVFGV-UHFFFAOYSA-N CN(C)C.C=1C=CC=CC=1C(=CC=CC=C)C1=CC=CC=C1 Chemical compound CN(C)C.C=1C=CC=CC=1C(=CC=CC=C)C1=CC=CC=C1 FZLOAWVDEJVFGV-UHFFFAOYSA-N 0.000 description 1
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
206010014759 Endometrial neoplasm Diseases 0.000 description 1
JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
229930186217 Glycolipid Natural products 0.000 description 1
102100036284 Hepcidin Human genes 0.000 description 1
SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
101001021253 Homo sapiens Hepcidin Proteins 0.000 description 1
101001105486 Homo sapiens Proteasome subunit alpha type-7 Proteins 0.000 description 1
206010058467 Lung neoplasm malignant Diseases 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
206010029155 Nephropathy toxic Diseases 0.000 description 1
206010061535 Ovarian neoplasm Diseases 0.000 description 1
102100021201 Proteasome subunit alpha type-7 Human genes 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
206010041067 Small cell lung cancer Diseases 0.000 description 1
208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
229930182558 Sterol Natural products 0.000 description 1
208000024313 Testicular Neoplasms Diseases 0.000 description 1
208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
238000010171 animal model Methods 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000000118 anti-neoplastic effect Effects 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
229940034982 antineoplastic agent Drugs 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
239000011324 bead Substances 0.000 description 1
230000005587 bubbling Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
235000011089 carbon dioxide Nutrition 0.000 description 1
229960004562 carboplatin Drugs 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
239000003638 chemical reducing agent Substances 0.000 description 1
229940044683 chemotherapy drug Drugs 0.000 description 1
150000001841 cholesterols Chemical class 0.000 description 1
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
238000009096 combination chemotherapy Methods 0.000 description 1
239000012468 concentrated sample Substances 0.000 description 1
230000003750 conditioning effect Effects 0.000 description 1
239000000470 constituent Substances 0.000 description 1
239000013078 crystal Substances 0.000 description 1
239000003599 detergent Substances 0.000 description 1
229910052805 deuterium Inorganic materials 0.000 description 1
238000011161 development Methods 0.000 description 1
150000001982 diacylglycerols Chemical class 0.000 description 1
238000011026 diafiltration Methods 0.000 description 1
238000009826 distribution Methods 0.000 description 1
GRWZHXKQBITJKP-UHFFFAOYSA-L dithionite(2-) Chemical compound [O-]S(=O)S([O-])=O GRWZHXKQBITJKP-UHFFFAOYSA-L 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
230000002357 endometrial effect Effects 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
229940031098 ethanolamine Drugs 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
230000029142 excretion Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
238000001125 extrusion Methods 0.000 description 1
238000000198 fluorescence anisotropy Methods 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
239000011521 glass Substances 0.000 description 1
229960005150 glycerol Drugs 0.000 description 1
238000011194 good manufacturing practice Methods 0.000 description 1
201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 1
150000002430 hydrocarbons Chemical group 0.000 description 1
238000009169 immunotherapy Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
229960000367 inositol Drugs 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
238000011005 laboratory method Methods 0.000 description 1
238000011031 large-scale manufacturing process Methods 0.000 description 1
201000005296 lung carcinoma Diseases 0.000 description 1
229940066294 lung surfactant Drugs 0.000 description 1
239000003580 lung surfactant Substances 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
230000007694 nephrotoxicity Effects 0.000 description 1
231100000417 nephrotoxicity Toxicity 0.000 description 1
208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
230000002611 ovarian Effects 0.000 description 1
229960001756 oxaliplatin Drugs 0.000 description 1
DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
239000002245 particle Substances 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
229940127557 pharmaceutical product Drugs 0.000 description 1
238000005191 phase separation Methods 0.000 description 1
150000008103 phosphatidic acids Chemical class 0.000 description 1
150000008105 phosphatidylcholines Chemical class 0.000 description 1
229940067605 phosphatidylethanolamines Drugs 0.000 description 1
150000003905 phosphatidylinositols Chemical class 0.000 description 1
239000000902 placebo Substances 0.000 description 1
229940068196 placebo Drugs 0.000 description 1
239000004417 polycarbonate Substances 0.000 description 1
229920000515 polycarbonate Polymers 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000000171 quenching effect Effects 0.000 description 1
238000011084 recovery Methods 0.000 description 1
238000005057 refrigeration Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
-1 seranide Chemical compound 0.000 description 1
229960001153 serine Drugs 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000011877 solvent mixture Substances 0.000 description 1
238000000527 sonication Methods 0.000 description 1
WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 1
238000001694 spray drying Methods 0.000 description 1
150000003432 sterols Chemical class 0.000 description 1
235000003702 sterols Nutrition 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
238000012360 testing method Methods 0.000 description 1
238000010257 thawing Methods 0.000 description 1
239000010409 thin film Substances 0.000 description 1
229930003799 tocopherol Natural products 0.000 description 1
239000011732 tocopherol Substances 0.000 description 1
125000002640 tocopherol group Chemical class 0.000 description 1
235000019149 tocopherols Nutrition 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
230000007704 transition Effects 0.000 description 1
DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1277—Preparation processes; Proliposomes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Dispersion Chemistry (AREA)
Inorganic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

ZA200501176A 2002-08-02 2005-02-09 Platinum aggregates and process for producing the same ZA200501176B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US40087502P	2002-08-02	2002-08-02

Publications (1)

Publication Number	Publication Date
ZA200501176B true ZA200501176B (en)	2006-09-27

Family

ID=32595039

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200501176A ZA200501176B (en)	2002-08-02	2005-02-09	Platinum aggregates and process for producing the same

Country Status (13)

Country	Link
US (1)	US20040101553A1 (de)
EP (1)	EP1545459A4 (de)
JP (1)	JP2006502233A (de)
KR (1)	KR20050038011A (de)
CN (1)	CN1681478A (de)
AU (1)	AU2003302314A1 (de)
BR (1)	BRPI0313191A2 (de)
CA (1)	CA2494673A1 (de)
IL (1)	IL166654A0 (de)
MX (1)	MXPA05001312A (de)
NZ (1)	NZ538179A (de)
WO (1)	WO2004054499A2 (de)
ZA (1)	ZA200501176B (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0011903D0 (en) *	2000-05-18	2000-07-05	Astrazeneca Ab	Combination chemotherapy
JP2005502653A (ja) *	2001-08-20	2005-01-27	トランセーヴ・インコーポレーテッド	肺ガンの治療方法
US9186322B2 (en)	2002-08-02	2015-11-17	Insmed Incorporated	Platinum aggregates and process for producing the same
AU2003304204B2 (en) *	2002-10-29	2009-12-24	Insmed Incorporated	Sustained release of antiinfectives
US7879351B2 (en) *	2002-10-29	2011-02-01	Transave, Inc.	High delivery rates for lipid based drug formulations, and methods of treatment thereof
US7718189B2 (en)	2002-10-29	2010-05-18	Transave, Inc.	Sustained release of antiinfectives
US20070065522A1 (en) *	2004-03-18	2007-03-22	Transave, Inc.	Administration of high potency platinum compound formulations by inhalation
AU2005223654A1 (en) *	2004-03-18	2005-09-29	Transave, Inc.	Administration of cisplatin by inhalation
AU2005245018A1 (en) *	2004-05-21	2005-12-01	Transave, Inc.	Treatment of lung diseases and pre-lung disease conditions
KR20070089693A (ko) *	2004-11-08	2007-08-31	트랜세이브, 인코포레이티드	지질-기재 플래티넘 화합물 제형을 복막내 투여하여 암을치료하는 방법
US20070190182A1 (en) *	2005-11-08	2007-08-16	Pilkiewicz Frank G	Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
WO2007056236A2 (en) *	2005-11-08	2007-05-18	Transave, Inc.	Methods of treating cancer with lipid-based platinum compound formulations administered intravenously
US9107824B2 (en)	2005-11-08	2015-08-18	Insmed Incorporated	Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
US20070122350A1 (en) *	2005-11-30	2007-05-31	Transave, Inc.	Safe and effective methods of administering therapeutic agents
ES2798263T3 (es)	2005-12-08	2020-12-10	Insmed Inc	Composiciones a base de lípidos de antiinfecciosos para tratar infecciones pulmonares
GR20060100144A (el) *	2006-03-03	2007-10-17		Θεραπεια του καρκινου με χρηση οξαλιπλατινης εγκλεισμενης μεσα σε λιποσωματα και απο κοινου εγκλεισμος στο λιποσωμιακο μοριο περισσοτερων απο ενος φαρμακευτικου παρασκευασματος h gene
US8168661B2 (en) *	2006-11-06	2012-05-01	Poniard Pharmaceuticals, Inc.	Use of picoplatin to treat colorectal cancer
US8173686B2 (en)	2006-11-06	2012-05-08	Poniard Pharmaceuticals, Inc.	Use of picoplatin to treat colorectal cancer
US8168662B1 (en)	2006-11-06	2012-05-01	Poniard Pharmaceuticals, Inc.	Use of picoplatin to treat colorectal cancer
US8178564B2 (en)	2006-11-06	2012-05-15	Poniard Pharmaceuticals, Inc.	Use of picoplatin to treat colorectal cancer
JP5364381B2 (ja) *	2006-12-08	2013-12-11	片山化学工業株式会社	アンミン白金錯体を高濃度で内包するリポソームおよびその製造方法
WO2008097658A1 (en) *	2007-02-09	2008-08-14	Poniard Pharmaceuticals, Inc.	Encapsulated picoplatin
CN104288119A (zh) *	2007-02-09	2015-01-21	英卡塔有限公司	稳定化的吡铂口服剂型
WO2008137717A1 (en)	2007-05-04	2008-11-13	Transave, Inc.	Compositions of multicationic drugs for reducing interactions with polyanionic biomolecules and methods and uses thereof
US9114081B2 (en)	2007-05-07	2015-08-25	Insmed Incorporated	Methods of treating pulmonary disorders with liposomal amikacin formulations
US9333214B2 (en)	2007-05-07	2016-05-10	Insmed Incorporated	Method for treating pulmonary disorders with liposomal amikacin formulations
US9119783B2 (en)	2007-05-07	2015-09-01	Insmed Incorporated	Method of treating pulmonary disorders with liposomal amikacin formulations
TW200920347A (en) *	2007-07-16	2009-05-16	Poniard Pharmaceuticals Inc	Oral formulations for picoplatin
AU2009210654A1 (en) *	2008-02-08	2009-08-13	Poniard Pharmaceuticals, Inc.	Use of picoplatin and bevacizumab to treat colorectal cancer
WO2009148169A1 (ja) *	2008-06-06	2009-12-10	片山化学工業株式会社	アンミン白金錯体を高濃度に内包するリポソームを用いた腫瘍治療技術
BRPI1008869A2 (pt) *	2009-02-04	2016-03-15	Brigham & Womens Hospital	nanopartícula, composto, composição farmacêutica, método para tratar câncer ou metástase, e, método de liberação prolongada de um composto de platina
PL2852391T3 (pl)	2012-05-21	2022-04-11	Insmed Incorporated	Układy do leczenia infekcji płuc
EP2892524B1 (de)	2012-09-04	2020-11-25	Eleison Pharmaceuticals, LLC	Prävention eines lungenkarzinomrezidivs mit lipidkomplexiertem cisplatin
US20150246137A1 (en) *	2012-09-27	2015-09-03	The University Of North Carolina At Chapel Hill	Lipid coated nanoparticles containing agents having low aqueous and lipid solubilities and methods thereof
CA2891487A1 (en)	2012-11-29	2014-06-05	Insmed Incorporated	Stabilized vancomycin formulations
MX384843B (es)	2014-05-15	2025-03-14	Insmed Inc	Métodos para tratar infecciones pulmonares micobacterianas no tuberculosas.
CN106955271A (zh) *	2016-01-08	2017-07-18	佛山英特医药科技有限公司	奥沙利铂聚集体及其制备方法
CN107260674A (zh) *	2016-04-06	2017-10-20	广州英特基因科技有限公司	卡铂聚集体及其制备方法
CN107303275A (zh) *	2016-04-22	2017-10-31	广州英特基因科技有限公司	吉非替尼脂质体复合物及其制备方法
CN107303276A (zh) *	2016-04-22	2017-10-31	广州英特基因科技有限公司	多西他赛脂质体复合物及其制备方法
EP3773505B1 (de)	2018-03-30	2026-04-29	Insmed Incorporated	Verfahren zur kontinuierlichen herstellung von liposomalen arzneimittelprodukten
EP3787602A4 (de)	2018-05-02	2022-03-23	Insmed Incorporated	Verfahren zur herstellung von liposomalen arzneimittelformulierungen
WO2021183588A1 (en) *	2020-03-10	2021-09-16	Chung Yuan Christian University	Liposome composition and preparation method thereof

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4451447A (en) *	1980-03-31	1984-05-29	Bristol-Myers Company	Pharmaceutical formulations
US4981692A (en) *	1983-03-24	1991-01-01	The Liposome Company, Inc.	Therapeutic treatment by intramammary infusion
USRE33071E (en) *	1983-03-28	1989-09-26		Platinum bound to transferrin for use in the treatment of breast tumors
US4590001A (en) *	1983-03-28	1986-05-20	Stjernholm Rune L	Platinum bound to transferrin for use in the treatment of breast tumors
US5019369A (en) *	1984-10-22	1991-05-28	Vestar, Inc.	Method of targeting tumors in humans
JPH0665648B2 (ja) *	1985-09-25	1994-08-24	塩野義製薬株式会社	白金系抗癌物質の安定な凍結真空乾燥製剤
US5041581A (en) *	1985-10-18	1991-08-20	The University Of Texas System Board Of Regents	Hydrophobic cis-platinum complexes efficiently incorporated into liposomes
US5117022A (en) *	1985-10-18	1992-05-26	The Board Of Regents, The University Of Texas System	Hydrophobic cis-platinum complexes efficiently incorporated into liposomes
US5049388A (en) *	1986-11-06	1991-09-17	Research Development Foundation	Small particle aerosol liposome and liposome-drug combinations for medical use
US5320906A (en) *	1986-12-15	1994-06-14	Vestar, Inc.	Delivery vehicles with amphiphile-associated active ingredient
CA1338702C (en) *	1987-03-05	1996-11-12	Lawrence D. Mayer	High drug:lipid formulations of liposomal- antineoplastic agents
US5616334A (en) *	1987-03-05	1997-04-01	The Liposome Company, Inc.	Low toxicity drug-lipid systems
MX9203808A (es) *	1987-03-05	1992-07-01	Liposome Co Inc	Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos.
IL83380A (en) *	1987-07-30	1991-04-15	Teva Pharma	Stable aqueous cisplatin solutions
CA1335348C (en) *	1988-03-04	1995-04-25	Yasuaki Ogawa	Liposome composition
US5141751A (en) *	1988-06-29	1992-08-25	Daiichi Pharmaceutical Co., Ltd.	Lipid membrane structures
US5549910A (en) *	1989-03-31	1996-08-27	The Regents Of The University Of California	Preparation of liposome and lipid complex compositions
US5013556A (en) *	1989-10-20	1991-05-07	Liposome Technology, Inc.	Liposomes with enhanced circulation time
US5756353A (en) *	1991-12-17	1998-05-26	The Regents Of The University Of California	Expression of cloned genes in the lung by aerosol-and liposome-based delivery
US5858784A (en) *	1991-12-17	1999-01-12	The Regents Of The University Of California	Expression of cloned genes in the lung by aerosol- and liposome-based delivery
EP0551169A1 (de) *	1992-01-10	1993-07-14	Takeda Chemical Industries, Ltd.	Liposomzusammensetzung und Verfahren
US5958449A (en) *	1992-12-02	1999-09-28	Nexstar Pharmaceuticals, Inc.	Antibiotic formulation and use for bacterial infections
US5665383A (en) *	1993-02-22	1997-09-09	Vivorx Pharmaceuticals, Inc.	Methods for the preparation of immunostimulating agents for in vivo delivery
US5780054A (en) *	1996-01-17	1998-07-14	University Of British Columbia	Methods for increasing the circulation half-life of protein-based therapeutics
EP0896816A4 (de) *	1996-02-26	2002-06-12	Daiichi Seiyaku Co	Liposom und liposomdispersion
PT910382E (pt) *	1996-04-26	2003-10-31	Genaera Corp	Esqualamina em combinacao com outros agentes anti-cancro para o tratamento de tumores
ATE252372T1 (de) *	1996-08-23	2003-11-15	Sequus Pharm Inc	Liposome enthaltend cisplatin
US5997899A (en) *	1996-10-01	1999-12-07	Skyepharma Inc.	Method for producing liposomes with increased percent of compound encapsulated
AU7711096A (en) *	1996-12-03	1998-06-29	Rijsuniversiteit Utrecht	Cisplatinum comprising pharmaceutical
US6451784B1 (en) *	1996-12-30	2002-09-17	Battellepharma, Inc.	Formulation and method for treating neoplasms by inhalation
NZ336381A (en) *	1996-12-30	2000-11-24	Battelle Memorial Institute	Formulation and method for treating neoplasms by inhalation
US6630168B1 (en) *	1997-02-20	2003-10-07	Biomedicines, Inc.	Gel delivery vehicles for anticellular proliferative agents
US6090407A (en) *	1997-09-23	2000-07-18	Research Development Foundation	Small particle liposome aerosols for delivery of anti-cancer drugs
US6787132B1 (en) *	1997-12-04	2004-09-07	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Combined chemo-immunotherapy with liposomal drugs and cytokines
US6726925B1 (en) *	1998-06-18	2004-04-27	Duke University	Temperature-sensitive liposomal formulation
CA2248592A1 (en) *	1998-08-31	2000-02-29	Christopher D. Batich	Microspheres for use in the treatment of cancer
US20050074499A1 (en) *	1999-03-17	2005-04-07	Mitsubishi Chemical Corporation	Ligand-bonded complex
US6723338B1 (en) *	1999-04-01	2004-04-20	Inex Pharmaceuticals Corporation	Compositions and methods for treating lymphoma
US6852334B1 (en) *	1999-04-20	2005-02-08	The University Of British Columbia	Cationic peg-lipids and methods of use
CA2377385A1 (en) *	1999-06-03	2000-12-14	Jessie L.S. Au	Methods and compositions for modulating cell proliferation and cell death
US6352996B1 (en) *	1999-08-03	2002-03-05	The Stehlin Foundation For Cancer Research	Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
US6511676B1 (en) *	1999-11-05	2003-01-28	Teni Boulikas	Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes
RU2270683C2 (ru) *	1999-12-04	2006-02-27	Рисерч Дивелопмент Фаундейшн	Увеличение эффективности ингаляционной терапии с помощью диоксида углерода
ATE341310T1 (de) *	2000-02-04	2006-10-15	Lipoxen Technologies Ltd	Dehydratisierungs-/rehydratisierungsverfahren zur herstellung von liposome
EP1299085B1 (de) *	2000-06-30	2005-11-16	Inex Pharmaceuticals Corp.	Verbesserte liposomale camptothecine und deren verwendungen
WO2002060412A2 (en) *	2001-02-01	2002-08-08	Board Of Regents	Stabilised polymeric aerosols for pulmonary gene delivery
AU2002249046A1 (en) *	2001-04-23	2002-11-05	Nucryst Pharmaceuticals Corp.	Lubricious coatings for substrates
ES2261735T3 (es) *	2001-05-18	2006-11-16	Chiron Corporation	Sistema para la administracion de una formulacion de tobramicina.
WO2003015698A2 (en) *	2001-08-13	2003-02-27	University Of Pittsburgh	Application of lipid vehicles and use for drug delivery
CA2457148A1 (en) *	2001-08-20	2003-02-27	Transave, Inc.	Treatment of cancers by inhalation of stable platinum-containing formulations
JP2005502653A (ja) *	2001-08-20	2005-01-27	トランセーヴ・インコーポレーテッド	肺ガンの治療方法

2003
- 2003-08-04 WO PCT/US2003/024350 patent/WO2004054499A2/en not_active Ceased
- 2003-08-04 EP EP03810869A patent/EP1545459A4/de not_active Withdrawn
- 2003-08-04 KR KR1020057001943A patent/KR20050038011A/ko not_active Ceased
- 2003-08-04 MX MXPA05001312A patent/MXPA05001312A/es unknown
- 2003-08-04 AU AU2003302314A patent/AU2003302314A1/en not_active Abandoned
- 2003-08-04 BR BRPI0313191A patent/BRPI0313191A2/pt not_active IP Right Cessation
- 2003-08-04 US US10/634,144 patent/US20040101553A1/en not_active Abandoned
- 2003-08-04 CN CNA038219891A patent/CN1681478A/zh active Pending
- 2003-08-04 NZ NZ538179A patent/NZ538179A/xx unknown
- 2003-08-04 JP JP2004560279A patent/JP2006502233A/ja active Pending
- 2003-08-04 CA CA002494673A patent/CA2494673A1/en not_active Abandoned
2005
- 2005-02-02 IL IL16665405A patent/IL166654A0/xx unknown
- 2005-02-09 ZA ZA200501176A patent/ZA200501176B/en unknown

Also Published As

Publication number	Publication date
KR20050038011A (ko)	2005-04-25
JP2006502233A (ja)	2006-01-19
IL166654A0 (en)	2006-01-15
NZ538179A (en)	2008-09-26
US20040101553A1 (en)	2004-05-27
AU2003302314A1 (en)	2004-07-09
WO2004054499A2 (en)	2004-07-01
CA2494673A1 (en)	2004-07-01
MXPA05001312A (es)	2005-08-03
EP1545459A2 (de)	2005-06-29
WO2004054499A3 (en)	2004-12-02
BRPI0313191A2 (pt)	2016-11-08
EP1545459A4 (de)	2007-08-22
CN1681478A (zh)	2005-10-12

Publication	Publication Date	Title
US20040101553A1 (en)	2004-05-27	Platinum aggregates and process for producing the same
JP4874547B2 (ja)	2012-02-15	勾配によるリポソームへの薬物充填方法
CA1339008C (en)	1997-03-25	Amphotericin b liposome preparation
HUE027467T2 (en)	2016-10-28	Liposomes or hydrochlorides of irinotecan and their preparation method
JPH11507369A (ja)	1999-06-29	プレリポソーム凍結乾燥体から得られるサブミクロンリポソーム懸濁液
CN114073678A (zh)	2022-02-22	稳定喜树碱药物组合物
JP2798302B2 (ja)	1998-09-17	リポソームおよび脂質複合体組成物の調製
EP1448165B1 (de)	2007-09-19	Lipidträgerzusammensetzungen und verfahren zur verbesserten wirkstoffzurückhaltung
CN103479578A (zh)	2014-01-01	一种马来酸匹杉琼的脂质体制剂及其制备工艺
CN107708670A (zh)	2018-02-16	磷脂包衣的治疗剂纳米颗粒和有关的方法
TW201711677A (zh)	2017-04-01	磷脂-膽固醇酯奈米調配物及其相關方法
JP2677576B2 (ja)	1997-11-17	非水溶性の有効成分のためのリン脂質輪送ビヒクル
JP2006510674A (ja)	2006-03-30	脂質：エモジン製剤に関する組成物および方法
US20030124180A1 (en)	2003-07-03	Liposomes containing active substances
US20160263030A1 (en)	2016-09-15	Platinum aggregates and process for producing the same
MXPA05007102A (es)	2005-08-26	Liposomas de larga circulacion sin peg.
CN109077997B (zh)	2023-04-07	培美曲塞二钠脂质复合物及其制备方法
Crommelin et al.	1986	Stability of liposomes on storage
US20060030578A1 (en)	2006-02-09	Pharmaceutically active lipid based formulation of irinotecan
JP2002509866A (ja)	2002-04-02	リポソーム様作用物質調剤の製造法
HK1150979B (en)	2019-08-02	Platinum aggregates and process for producing the same
HK40070304A (en)	2022-10-28	Stabilizing camptothecin pharmaceutical compositions
HK40065453A (en)	2022-07-29	Stabilizing camptothecin pharmaceutical compositions
CN107260674A (zh)	2017-10-20	卡铂聚集体及其制备方法
CN106955271A (zh)	2017-07-18	奥沙利铂聚集体及其制备方法